What type of cancer is Daurismo (glasdegib) used to treat?
What type of drug is Daurismo?
Medically reviewed by Drugs.com. Last updated on Dec 2, 2020.
Daurismo (glasdegib) is an oral hedgehog pathway inhibitor used with low-dose cytarabine (LDAC) chemotherapy for newly-diagnosed acute myeloid leukemia (AML) in adults 75 years or older or for patients unable to use intensive chemotherapy.
- AML is a blood and bone marrow cancer that leads to abnormal white blood cells, bruising, fatigue, and infections.
- Many adults with AML are unable to have intensive chemotherapy due to toxicity.
- Daurismo may be a more tolerable option for some AML patients.
The hedgehog pathway is a novel therapeutic cancer target. The hedgehog signaling pathway is involved in the normal, early stages of cell growth of a fetus. However, mutation of this pathway in adults can lead to the development of certain cancers, such as skin, brain, pancreatic, prostate, and lung cancers and hematological malignancies like AML.
Related Medical Questions
- Oxycodone vs Hydrocodone - How do they compare?
- How long should you take Lupron for prostate cancer?
- Vicodin vs Percocet: What's the difference?
- How effective is Casodex (bicalutamide) for prostate cancer?
- How does Lupron (leuprolide) work for prostate cancer?
- How does Ibrance kill cancer?
- Can Darzalex cure Multiple Myeloma?